Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: J Thorac Cardiovasc Surg. 2015 Oct 19;151(4):969–979.e3. doi: 10.1016/j.jtcvs.2015.09.127

Figure 2.

Figure 2

Disease-free survival (DFS). A, Entire cohort: the 5-year DFS was 23% (95% CI, 14%–37%). B, Postinduction PET N2 status: the 5-year DFS for N2-negative was 24% (95% CI, 11%–51%) vs 24% (95% CI, 11%–54%) for N2-avid disease (p=0.867). C, Pathologic N2 status: the 5-year DFS for N2-negative was 34% (95% CI, 21%–56%) vs 9% (95% CI, 2%–45%) for N2-persistent disease (p=0.079). D, Pathologic staging: the 5-year DFS for <ypIIIA was 36% (95% CI, 22%–58%) vs 9% (95% CI, 2%–44%) for ≥ypIIIA (p=0.054).